Cabometyx® (cabozantinib) – New indication
On September 17, 2021, Exelixis announced the FDA approval of Cabometyx (cabozantinib), for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
Top